NEC Oncoimmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. We are dedicated to developing scalable software solutions that facilitate effective patient selection for cancer immunotherapy and identifying optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame. Our growing international team (13 countries and counting!) consists of a diverse mix of data scientists, bioinformaticians, immunologists, cancer researchers, and software developers. NEC Oncoimmunity AS is a subsidiary of the NEC Corporation and is based in the Oslo Cancer Cluster buildings in Oslo, Norway.
Something looks off?